Ftse Mib
38.421,05
0,45%
DAX
22.287,56
-0,24%
S&P 500
6.013,13
-1,71%
NASDAQ
19.524,01
-2,20%
Bitcoin
96.524,27
0,40%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aligos Therapeutics Inc (ALGS) Aligos Therapeutics Inc (ALGS) Notizie

Aligos Therapeutics Inc

ALGS
19,50
-1,35 (-6,47%)
22 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/2/202514:52EDGAR2Form 8-K - Current report
12/2/202513:00GLOBEAligos Therapeutics Announces $105 Million Private Placement..
03/2/202522:02EDGAR2Form 8-K - Current report
13/12/202414:00GLOBEAligos Therapeutics Announces Inducement Grants Under Nasdaq..
26/11/202414:00GLOBEAligos Therapeutics to Present at Investor Conferences in..
19/11/202419:30GLOBEAligos Therapeutics Presents Positive Data at The Liver..
19/11/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
06/11/202423:14EDGAR2Form S-3 - Registration statement under Securities Act of..
06/11/202422:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202422:05GLOBEAligos Therapeutics Reports Recent Business Progress..
06/11/202422:05EDGAR2Form 8-K - Current report
30/10/202421:05GLOBEAligos Therapeutics to Announce 3rd Quarter 2024 Financial..
22/10/202414:00GLOBEAligos Therapeutics Announces U.S. FDA Clearance of IND..
15/10/202415:00GLOBEAligos Therapeutics Announces Acceptance of Abstracts on..
11/10/202414:00GLOBEAligos Therapeutics Announces Inducement Grants Under Nasdaq..
10/10/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/10/202414:00GLOBEAligos Therapeutics Appoints David Perry as Vice President..
30/9/202414:00GLOBEAligos Therapeutics to Present at Investor Conferences in..
26/9/202422:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
24/9/202414:00GLOBEAligos Therapeutics Strengthens Senior Leadership Team with..
19/9/202414:00GLOBEAligos Therapeutics Announces Positive Topline Results from..
18/9/202423:00GLOBEAligos Therapeutics to Announce Topline Results from the..
13/9/202414:00GLOBEAligos Therapeutics Announces Inducement Grants Under Nasdaq..
06/9/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:06EDGAR2Form 8-K - Current report
19/8/202422:05EDGAR2Form 8-K - Current report
15/8/202415:00GLOBEAligos Therapeutics Announces Reverse Stock Split
09/8/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202422:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/8/202422:11EDGAR2Form 8-K - Current report
08/8/202422:05GLOBEAligos Therapeutics Strengthens Board with Two New..
06/8/202422:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/8/202422:05EDGAR2Form 8-K - Current report
06/8/202422:05GLOBEAligos Therapeutics Reports Recent Business Progress..
30/7/202422:05GLOBEAligos Therapeutics to Announce 2nd Quarter 2024 Financial..
22/7/202415:00GLOBEAligos Therapeutics Announces Clinical Collaboration with..
10/7/202414:00GLOBEAligos Therapeutics to Host KOL Event to Discuss the..
05/6/202408:30GLOBEAligos Therapeutics Presents Positive Data at the EASL..
31/5/202422:05EDGAR2Form 8-K - Current report
22/5/202422:05GLOBEAligos Therapeutics Announces Six Abstracts Accepted for..
22/5/202422:02EDGAR2Form 8-K - Current report
21/5/202414:00GLOBEAligos Therapeutics Announces the Completion of Enrollment..
15/5/202423:01EDGAR2Form 8-K - Current report
07/5/202422:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202422:05EDGAR2Form 8-K - Current report
07/5/202422:05GLOBEAligos Therapeutics Reports Recent Business Progress..
30/4/202422:05GLOBEAligos Therapeutics to Announce 1st Quarter 2024 Financial..
25/4/202422:05GLOBEAligos Therapeutics Presents Positive Clinical Data at..
25/4/202414:00GLOBEAligos Therapeutics Mourns the Passing of MASH Industry..
09/4/202414:00GLOBEAligos Therapeutics to Participate in the Piper Sandler..
Apertura: 21,47 Min: 18,13 Max: 21,88
Chiusura: 20,85

La tua Cronologia

NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci